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It is widely recognized nowadays that complex diseases are caused by, amongst the others, multiple genetic factors. The recent 
advent of genome-wide association study (GWA) has triggered a wave of research aimed at discovering genetic factors underlying 
common complex diseases.  While the number of reported susceptible genetic variants is increasing steadily, the application of such 
findings into diseases prognosis for the general population is still unclear, and there are doubts about whether the size of the 
contribution by such factors is significant. In this respect, some recent simulation-based studies have shed more light to the prospect 
of genetic tests. In this report, we discuss several aspects of simulation-based studies: their parameters, their assumptions, and the 
information they provide. 
 
 
1. Introduction 
It is widely recognized nowadays that complex 
diseases are caused by, amongst the others, multiple 
genetic factors.1-4 The recent advent of genome-wide 
association study (GWA) has triggered a wave of research 
aimed at discovering genetic factors underlying common 
complex diseases.  While the number of reported 
susceptible genetic variants is increasing steadily, the 
application of such findings into diseases prognosis for 
the general population is still unclear, and there are doubts 
about whether the size of the contribution by such factors 
is significant.5 In this respect, simulation-based studies 
such as that conducted by Yang et. al.,6 and more recently 
by Janssens et. al.,7 are interesting and welcome 
contributions. While the former study showed that 
multiple genetic susceptibility tests (composed of up to 5 
genes) significantly improve the prediction of 
multifactorial diseases, the latter was a more 
comprehensive study showing the prognostic accuracy of 
genetic tests composed of up to 400 genes, with various 
different scenarios for the risk allele frequencies and 
genotypes’ odd ratios.  In this report, we discuss several 
aspects of simulation-based studies, such as their model 
parameters, their assumptions, the information that they 
provide and more importantly, how to design a proper 
simulation methodology.  
 
2. Background and Methods 
As a common practice in the medical research 
literature, in this study we employ a Bayesian approach 
calculate the posterior probability of developing the 
disease given the genetic test results. Let D and Do  
represent the diseased and non-diseased population 
respectively. Let p = P(D) be the prior probability of 
developing the disease, also known as the disease 
prevalence or background risk, which tells us how likely a 
person chosen at random from the population is 
developing the disease, if no further information was 
available.  
Let G={g1,g2,…,gn} be the vector of test results for n 
disease susceptibility genes. Now in the light of further 
evidences, i.e. the genetic test results G, the Bayes’ rule 
can be employed to estimate the posterior risk of 
developing the disease: 
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then it can be shown that the posterior probability of 
developing the disease given a particular genetic test 
results is: 
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Thus in order to calculate the post-test probability of 
developing the disease, we need to know the likelihood 
ratio of the genetic profile G. 
 
2.1 Likelihood ratio estimation 
If the n genes are independent then: 
P(G|D)=P(g1|D) P(g2|D)… P(gn|D)  
and similarly: 
P(G|Do) =P(g1|Do) P(g2|Do)… P(gn|Do). 
It follows that: 
                   LR(G)=LR(g1) LR(g2)…LR(gn) (4) 
Thus the likelihood ratio of a panel of independent test 
is simply the product of the likelihood ratios of the 
individual test results. As we shall see later, the 
likelihood ratios of the genotypes for each gene can be 
theoretically inferred, provided that information such as 
risk allele frequency, disease prevalence and odd ratios 
(or relative risk) of the risk genotypes is available. In 
practice, when such information is not always available, 
Yang et. al.6 proposed a logistic regression based 
method in conjunction with a case-control study to 
estimate the likelihood ratios. More specifically, they 
showed that if a case-control study is designed such that 
there are NCO subjects in the control group and NCA 
subjects in the case group, then: 
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where αCC and β  are the intercept term and logistic 
regression coefficients of the odds of developing the 
disease respectively. 
 
2.2 Performance evaluation 
We consider first a single binary genetic test G={g1} of 
which the value can take on only two values: 0 (negative) 
corresponding to the case of the gene is a homozygous 
non-risk genotype, and 1 (positive) otherwise.  Various 
quality measures for binary test are presented in Table 1. 
Table 1: Quality measures for a binary test. 
Single-
gene 
test 
outcome 
Disease status  
D 
(Diseased) 
Do 
(Non-diseased) 
 
Positive TP – True positive 
FP – False 
Positive 
(Type I error, 
P-value) 
Positive 
Predictive 
Value: 
PPV = 
TP/(FP+TP) 
Negative 
FN - False 
Negative 
(Type II Error) 
TN – True 
Negative 
Negative 
Predictive 
Value: 
NPV = 
TN/(FN+TN) 
 Sensitivity = 
TP/(TP+FN) 
Specificity = 
TN/(FP+TN) 
 
 
For the case of multiple-gene tests G={g1,g2,…,gn}, if for 
each gene the test can take on two values, either negative 
or positive as considered by Yang et. al.,6 then there 
would be 2n different test results in the population. If a 
more detailed genetic model is assumed as by Janssens et. 
al.,7 where the test result for each gene can take on three 
different values corresponding to the homozygous non-
risk, heterozygous and homozygous risk genotypes, then 
there are 3n different test results in the population. For 
these cases, in order to predict the disease status of a 
subject, one need to binarize its test result, i.e. make a 
final decision whether it is positive or negative. The 
decision can be made based upon choosing a suitable cut-
off value for the posterior probability P(D|G). Each cut-
off value results in a different value of the test sensitivity 
and specificity, and there is often trade-off between these 
two quality measures. The discriminative accuracy of a 
multiple-gene test can be assessed by the area under 
receiver operating characteristic (ROC) - the plot of the 
sensitivity vs. (1 - specificity) for a test as its cut-off value 
is varied. 
 
3. Simulation models 
3.1 A simple simulation model  
In this section we reconsider the simulation study carried 
out by Yang et. al.6 In this study the test result for each 
gene can take on two different values: 0 corresponding to 
the case of homozygous non-risk genotype, and 1 
otherwise. All genes were assumed to be independent. To 
estimate the likelihood ratio of a Genetic test profile G, 
Yang et. al. employed a logistic regression model (as 
describe above), with a further assumption that genes 
interact multiplicatively. They reported the simulation 
results for genetics test composed of up to 5 genes, which 
included the likelihood ratio obtained from a simulated 
case-control study along with the 95% confidence 
interval. While estimating the likelihood ratio from a 
case-control study is certainly useful in practice, in our 
opinion, in a simulation study where information such as 
disease prevalence p, risk allele frequency f, and relative 
risk R of risk genotypes, are available and controllable, it 
is more interesting to theoretically calculate the 
likelihood ratios. Likelihood ratio for each gene can be 
calculated based on Table 2. 
Table 2: Basic table for calculating likelihood ratio of a 
binary single-gene test 
Single-
gene test 
outcome 
Disease status 
Total D 
(Diseased) 
Do 
(Non-
diseased) 
1 A B fN 
0 C D (1-f)N 
Total pN (1-p)N N 
 N: number of subjects in the study 
 
The number of subjects in each category can be 
logically derived from the model parameters f, p and R. 
More specifically, A, B, C, D is determined from the 
below equation system: 
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of which an analytical solution can easily derived, and 
then the likelihood ratio of the test results can be 
calculated as:  
                                   
))1/((
/)1(
NpB
pNALR
−
=  (7) 
and    
                                   
))1/((
/)0(
NpD
pNCLR
−
=  (8) 
The combined likelihood ratio of a multiple-gene test 
outcome can then be calculated by multiplying the 
likelihood ratios of its component test results. The 
likelihood ratio obtained is not an estimate but a single 
“true” value. Reporting this value seems to be more 
relevant than the value obtained from a simulated case-
control study on a simulated population, since reflects 
the intrinsic ability of a multiple-gene test in 
discriminating the diseased group from the non-
diseased group. 
Based on our analysis, we re-perform the experiment 
corresponding to Table 1 in Yang et. al.’s paper. We 
consider genetic tests composed of up to 5 genes with 
relative risk ranging from 1.5 to 3.5, and gene 
frequency from 5% to 25%. Results are reported in 
Table 3. It can be observed that the estimated likelihood 
ratios deviate more from the “true” likelihood ratios 
when the number of gene in the model increases. In 
fact, our experiments (data not shown) have showed 
that when the number of subjects in the simulated case-
control study is increased, e.g from 1000 to 10,000 
subjects, then the estimated LR value gets very close to 
the true LR value. This is to be expected, since the 
accuracy of an unbiased estimator increases as the 
sample size increases. The estimated value might be 
lower or higher than the true value, reflecting the fact 
that it is not trivial to exactly estimate population 
parameters from a limited number of samples.  We 
stress again that it is the “true” LR value which decides 
the theoretical intrinsic discriminative accuracy of a 
genetic test, and that why this value is of interest. 
 
Table 3: Likelihood ratios and posterior probability of developing disease. Background risk p = 5%. 
Genetic tests 
Relative risk of 
genotype Gene frequency Estimated LR (95% CI)* “True” LR 
Posterior probability 
of developing disease 
(%) 
One-gene tests: 
g1 1.5 25 1.72 (1.37-2.16) 1.36 6.7 
g2 2.0 20 1.61 (1.22-2.13) 1.72 8.3 
g3 2.5 15 2.10 (1.55-2.85) 2.16 10.2 
g4 3.0 10 2.75 (1.88-4.03) 2.71 12.5 
g5 3.5 5 3.72 (2.21-6.26) 3.50 15.6 
Two-gene tests (selected examples): 
g1 1.5 25 2.95 (2.07-4.20) 2.34 11 g2 2.0 20 
      
g1 1.5 25 3.6 (2.49-5.21) 2.93 13.4 g3 2.5 15 
      
g2 2.0 20 3.26 (2.2-4.84) 3.72 16.4 
g3 2.5 15 
Three-gene tests (selected examples): 
g1 1.5 25 
6.02 (3.79-9.56) 5.05 21 g2 2.0 20 
g3 2.5 15 
Four-gene tests (selected examples): 
g1 1.5 25 
19.0 (10.5-35.6) 13.69 41.9 g2 2.0 20 g3 2.5 15 
g4 3.0 10 
Five-gene tests: 
g1 1.5 25 
151.7 (64.9-354.8) 47.9 71.6 
g2 2.0 20 
g3 2.5 15 
g4 3.0 10 
g5 3.5 5 
* results reported in Yang et. al, 6 estimated through a single simulated case-control study on a simulated population of N=1,000,000 subjects. 
 
3.2 A more detailed simulation model 
Janssens et al.7 considered a more detailed genetic model 
where each gene has two alleles and three genotypes, i.e. 
the homozygous non-risk genotype ee, the homozygous 
risk genotype EE, and the heterozygous risk genotype Ee. 
Their study showed that it is theoretically possible to 
construct effective prognosis mechanisms based solely 
upon genetic profiling. The discriminative accuracy, 
evaluated by the area under the receiver-operating curve 
(AUC), can reach as high as 0.90 or more, using a test 
composed of multiple susceptibility genes, each with 
modest elevated relative risk. This simulation method has 
been employed in several subsequent studies.1, 2, 8 In one 
of our current osteoporosis studies, a similar simulation 
strategy is being carried out to determine the contribution 
of genetic factors in the prognosis of bone fracture, on top 
of other clinical factors such as age, bone mineral density, 
history of fractures and falls. During the course of 
constructing the simulation study, we have proposed some 
changes and improvements that, in our opinion, may 
contribute both to the theoretical soundness and practical 
efficiency of the simulation methodology.  
We first provide here a brief review of the original 
simulation procedure proposed by Janssens et al.7, 
composed of three steps. The simulation model admits the 
following main parameters, namely the number of 
subjects in the studies, N, often set to 100,000; the 
number of genes in the study, M; the disease prevalence 
p; the allele frequencies f={f1, f2,…, fM} where fi 
corresponds to the i-th gene;  and the Odds Ratio OR =  
{OR1, OR2,…, ORM}  of the heterozygous genotype 
corresponding to each gene. 
 
Janssens et al. simulation procedure for complex 
diseases prediction using multiple genes7: 
Step 1 - Modeling genetic profiles: Genetic 
profiles are built, consisting of up to M = 400 genes. 
Assuming that each single gene has two alleles and that 
all genotype and allele proportion were in Hardy-
Weinberg equilibrium, the number of each genotype in 
the population can be calculated based on the parameter 
f. For each gene, a vector of length N is created, 
containing the genotypes corresponding to N subjects 
under study, with proportion of each genotype as 
specified by the parameter f.  Each subject is assigned a 
genotype by randomly sampling (without replacement) 
this vector. 
Step 2 – Modeling disease risk associated with 
genetic profiles: The disease risk associated with the 
genetics profiles is calculated using the Bayes' theorem: 
Posterior_odds=LR_of_Genetic_profile × prior_odds 
where prior_odds = p/(1-p) with p being the disease 
prevalence parameter. Assuming no interaction between 
genes, the Likelihood Ratio (LR) of a genetic profile 
can be obtained by multiplying the LRs of the single 
genotypes:  
∏
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The LR of a single genotype is the percentage of the 
genotype among subjects who will develop the disease 
divided by the percentage of the genotype among 
subjects who will not develop the disease. The LR is 
calculated from Table 4. 
 
Table 4: Number of genotypes of the i-th gene in the 
population 
Genotype Subject 
with 
disease 
Subject 
without 
disease 
Total 
EEi A B fi2N 
Eei C D 2fi(1-fi )N 
eei E G (1-fi )2N 
Total Np N(1-p) N 
 
The Odds Ratio of the heterozygous risk genotype Eei of 
the i-th gene, is given as a model parameter, namely ORi, 
while the Odds Ratio of the homozygous risk genotype 
EEi is assumed to be the square of ORi. In order to 
calculate the LRs, the value of A-G must be determined 
through solving the following equation system: 
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Then the LR of each genotype for the i-th gene can be 
calculated as: LR(EEi)=A(1-p)/(Bp); 
LR(Eei)=C(1-p)/(Dp) and  LR(eei)=E(1-p)/(Gp). 
 
Step 3- Modeling disease status: The disease risk 
of each subject is compared with a randomly drawn value 
between 0 and 1 from a uniform distribution.  A subject is 
assigned to the group who will develop the disease when 
the disease risk is higher than the random value and to the 
group who will not develop the disease otherwise. This 
procedure ensures that subjects with high disease risks are 
more likely to be assigned to the group who will develop 
the disease than those with low risks. 
 
After all the three steps have been completed, we have in 
hand a simulated population with known disease status 
and known risk profile. The data can then be statistically 
analysed, for example, by calculating the AUC of a 
prognosis test built upon the genetic profile using the 
Bayesian risk model described above. During the course 
of our experiment with the simulation procedure 
described above, we noticed several points that might be 
further improved. 
 
The first proposed improvement involves the solution of 
equation (9).  Despite its modest appearance, it is rather 
difficult to solve this equation system analytically. In the 
absence of a closed form solution, Janssens et al. 
(personal communications) resorted to a heuristic iterative 
algorithm briefly described as follows: starting with A=1, 
with knowledge of the genotype frequencies, the value for 
B can be inferred. Table 4 then essentially reduces to a 
2x2 table of the 4 unknown variables C-G (similar to 
Table 2), for which the values can be filled in analytically. 
The odds ratio of AG/BE is then checked; if it is too low 
then A is increased by one. The process is repeated until 
AG/BE becomes close enough to (ORi)2.  While this 
algorithm seems to work in practice, an analytical 
solution for (9) is still of great interest, both for the 
theoretical soundness of the simulation methodology and 
for its efficient implementation, since the number of 
repeated experiments is often huge. 
 
Indeed, we are now showing that such a closed form 
solution is achievable. Let t1, t2, t3, t4, t5 denote the 
values of fi2N, 2fi(1-fi)N, (1-fi)2N, pN and ORi 
respectively, by careful algebraic manipulation it is 
possible to show that the value of D is given by a 
suitable solution of a third order polynomial equation of 
the form: 
A3 D3+A2 D2+A1D+A0=0 
where the coefficients are given by: 
A3=1-2t5+t52 
A2=-t1t52-2t5t4+t4+t5t1+t3t5-t3+4t5t2-2t2+t4t52-2t2t52 
A1=t3t2-2t1t5t2+2t4t5t2+t1t52t2-2t5t3t2-t4t2+t22-t4t52t2-
3t5t22+t22t52 
A0=-t5t4t22+t5t1t22+t5t3t22+t5t23 
 
Since a closed form solution for third order polynomial 
equation exists, finding the closed form solution for D 
from this equation, and subsequently the suitable values 
for A-G is rather straightforward. A short program in 
the R software for this purpose is available from us 
upon request. 
 
The second major proposed modification in the 
simulation procedure involves the following 
observation: the proportion of subjects developing the 
disease in the obtained simulated population, denoted 
by p’, is often smaller than the disease prevalence as 
prescribed by the parameter p, and the gap grows as the 
number of genes in the study gets larger. For example, 
let p=0.3, then when the number of genes M=100, p’ is 
only ~0.26 and this figure reduces to ~0.22 when 
M=200 and only ~0.17 when M=400. Since p≠p’, a 
question arises as to what the real meaning of the 
parameter p is.  Since p represents the disease 
prevalence in the population, it is probably preferable 
that the proportion p’ of subjects developing the disease 
in the simulated population is kept close to p or ideally 
exactly equal to p. So where does the inconsistency 
come from? Pondering this question, we turn to the 
following, more basic conceptual question of cause and 
consequence: is the disease risk value (as predicted by a 
prognosis model such as the Bayesian model described 
above) the cause or the consequence of the disease 
status? The answer is probably clear: the disease risk 
value is the consequence of the disease status. In the 
simulation procedure employed by Janssens et al.,7 this 
cause-consequence relationship has been reversed, i.e., 
in step 3, the disease status is the consequence of the 
disease risk value predicted by the Bayesian model.  If 
another risk model, such as the logistic model, were 
employed simultaneously for comparison, then possibly 
the disease status of a subject derived from the two 
models would be different.  This is again another 
inconsistency since the value of a predictive test should 
only give a prediction about the disease status, but not 
modify the “true” disease status of a subject. 
 
To rectify the above stated inconsistencies, it is 
necessary to make a major change in the conceptual 
design of the simulation method, that is, to put the 
objects in the right place in the cause-consequence 
relationship. In light of our analysis above, we propose 
a new simulation procedure as follows (compare with 
the above procedure by Janssens et al.7): 
            Step 1- Modeling disease status: create two groups 
of subjects containing correspondingly Np subjects who is 
developing the disease, and N(1-p) subjects who will is 
not. 
           Step 2 - Modeling genetic profiles: for each gene, 
solve equation (9) to fill in Table 4.  Now for each group 
we can create a genetic pool where the number of each 
genotype is prescribed by Table 4. Next, assign each 
subject a random genotype by randomly sampling, 
without replacement, the pool corresponds to its group.  
Repeat the same process for all genes in the simulation. 
            Step 3 – Modeling disease risk associated with 
genetic profiles: in this final step, a predictive test based 
on the genetic profile is built. Examples are the above 
describe Bayesian model, or a logistic model.  
 
With this new simulation procedure, the simulated 
population obtained now closely reflects the intended 
population as prescribed by the set of model parameters. 
We repeated the simulation corresponding to Figure 2 in 
the paper by Janssens et al.7 In particular, the 
discriminative accuracy (in terms of the area under the 
ROC) for multiple-gene tests consisted of one to 400 
genes was calculated. The risk allele frequency for all 
genes was set to 10%, and the ORs for all genes was the 
same. Our simulation results, presented in Figure 1, 
showed a slight difference from that reported by Janssens 
et al.7, especially when the number of genes in the 
simulation is higher, where the difference of p and p’ in 
Janssens et al.’s simulation procedure is large. More 
specifically, our AUC value obtained at such values of M 
is slightly higher. Though the difference seems to be 
minor in this particular scenario, we nevertheless 
advocate the use of our simulation model for its 
consistency and implementation efficiency. 
Using the likelihood ratios calculated from Table 4 it is 
also able to answer another interesting question: how 
many genes are needed for a PPV value five times greater 
than the background risk? We assume that all genes 
contain a risk genotype, i.e. being either EE or Ee, and 
have the same OR for the heterozygous risk genotype (the 
OR for the homozygous risk genotype is assumed to be 
the square of the OR for the heterozygous risk genotype). 
Clearly, the smallest number of genes needed for a 
particular PPV is achieved when all genotypes in the test 
are EE’s, and the most number is required when all 
genotypes are Ee’s. Results are reported in Table 5. 
 
Figure 1. Discriminative accuracy, evaluated by the area under 
the ROC (AUC), of multiple-gene tests. Disease prevalence 
p=10%, risk allele frequency is 10% for all genes. The numbers 
next to each line represents the OR for the heterozygous 
genotype of all genes included in the test..   
 
Table 5: Number of genes needed for a PPV value 5 times 
greater than the background risk p which is set to 10%. OR’s 
for all genes are the same. All genes are assumed to bear risk 
allele. 
OR Number of genes needed Smallest Largest 
1.05 29 76 
1.10 15 40 
1.25 7 18 
1.5 4 10 
3.0 2 5 
5.0 1 4 
 
In summary, in this report we have discussed several 
aspects of simulation based studies for assessing the 
prospect of genetic testing. We discussed several 
previous simulation-based studies and proposed 
simulation procedure, which is more efficient and 
consistent. Using this procedure, it is also possible to 
assessed the effectiveness of genetic test on top of other 
classical clinical factor and this is one of our ongoing 
work.  
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